LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of LifeMap Discoveryâ„¢ version 1.5 (discovery.lifemapsc.com). LifeMap Discoveryâ„¢ is a state-of-the-art roadmap of embryonic development and stem cell biology. The product integrates embryonic development and stem cell biology, molecular, cellular, anatomical, and disease-related information, and provides data-mining capabilities and bioinformatics applications. As such, it is a unique and powerful tool for research and discovery in multiple disciplines, including stem cell biology, developmental biology, disease mechanisms and etiology.
LifeMap Discovery™ is a key component in LifeMap’s integrated database suite, a discovery platform for biomedical and stem cell research, which also includes GeneCards®, the leading human gene database (www.genecards.org), and MalaCards, the human disease database (www.malacards.org). LifeMap Sciences holds the exclusive worldwide license to market GeneCards® and MalaCards from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science.
Version 1.5 of LifeMap Discoveryâ„¢ includes the following new features: